Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema

Trial Profile

A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glibenclamide (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms GAMES-RP
  • Sponsors Remedy Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2019 Results published in the Stroke
    • 08 Feb 2019 Results assessing the effect of Glibenclamide on Water Uptake and Mass Effect in Large Hemispheric Infarction, presented at the International Stroke Conference 2019
    • 22 May 2018 Results (n=86) efficacy and tolerability of glibenclamide [CIRARA; Remedy Pharmaceuticals] in patients with a severe anterior circulation ischaemic stroke who are likely to develop malignant oedema, were published in the Stroke.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top